https://www.pharmaradar360.com/article/the-5-most-interesting-analyst-questions-from-west-pharmaceutical-services-s-q2-0990d0cfc1c0a4b2Pharma Surgeen2026-08-01T14:59:57.000ZThe 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Callhttps://www.pharmaradar360.com/article/nafdac-joins-the-federal-ministry-of-health-and-social-welfare-nutrition-partner-59bc7b4ca73e2c7cPharma Surgeen2026-08-01T13:01:42.000ZNAFDAC joins the Federal Ministry of Health and Social Welfare, nutrition partners, and the global community in celebrating World Breastfeeding Week 2026https://www.pharmaradar360.com/article/top-portage-biotech-alp-competitors-2026-f77a722fc11c05f7Pharma Surgeen2026-08-01T12:13:19.000ZTop Portage Biotech (ALP) Competitors 2026https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kolmar-biotech-inc-krx-215380-c5226d0b372e4e11Pharma Surgeen2026-08-01T11:23:37.000ZEnterprise value to EBIT forward of Kolmar BioTech. Inc. – KRX:215380https://www.pharmaradar360.com/article/why-drug-safety-has-become-india-s-next-pharmaceutical-imperative-0220321938f75a9fPharma Surgeen2026-08-01T10:46:53.000ZWhy Drug Safety Has Become India's Next Pharmaceutical Imperativehttps://www.pharmaradar360.com/article/janus-henderson-group-plc-has-145-08-million-position-in-teva-pharmaceutical-ind-9265df161f0885d9Pharma Surgeen2026-08-01T10:32:33.000ZJanus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-c7d412bd268a27acPharma Surgeen2026-08-01T10:13:28.000ZEbola disease caused by Bundibugyo virus - Democratic Republic of the Congohttps://www.pharmaradar360.com/article/krystal-biotech-inc-krys-valuation-pe-pb-fair-value-analysis-3b997157c5aec021Pharma Surgeen2026-08-01T09:37:27.000ZKrystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysishttps://www.pharmaradar360.com/article/axiom-investment-management-llc-takes-965-000-position-in-teva-pharmaceutical-in-fdd38569a8949237Pharma Surgeen2026-08-01T08:40:51.000ZAxiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/moleculin-biotech-mbrx-us-synthetic-expert-call-transcript-01-aug-2026-4388bb4781182970Pharma Surgeen2026-08-01T08:36:50.000ZMoleculin Biotech (MBRX US): Synthetic Expert Call Transcript (01 Aug 2026)https://www.pharmaradar360.com/article/sichuan-kelun-biotech-sehk-6990-wins-priority-review-for-sixth-sac-tmt-indicatio-3bcacf2c19b9ac8cPharma Surgeen2026-08-01T08:30:51.000ZSichuan Kelun Biotech (SEHK:6990) Wins Priority Review For Sixth Sac TMT Indicationhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-08-01T07:49:04.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stake-boosted-by-avidity-partners-manage-cd336bd1caf2e954Pharma Surgeen2026-08-01T07:48:40.000ZTeva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Avidity Partners Management LPhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-us-will-release-its-earnings-report-before-the-mar-6463506595785845Pharma Surgeen2026-08-01T07:42:11.000ZCollegium Pharmaceutical (COLL.US) will release its earnings report before the market opens on August 6.https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-lushang-freda-pharmaceutical-co-ltd-class-1b3077d39a43419cPharma Surgeen2026-08-01T07:40:20.000ZEnterprise value to EBITDA forward of Lushang Freda Pharmaceutical Co., Ltd. Class A – SSE:600223https://www.pharmaradar360.com/article/vidipha-central-pharmaceutical-jsc-revenue-breakdown-hose-vdp-e54903770464339ePharma Surgeen2026-08-01T06:47:50.000ZVidipha Central Pharmaceutical JSC Revenue Breakdown – HOSE:VDPhttps://www.pharmaradar360.com/article/keros-receives-20m-milestone-as-elritercept-phase-3-trial-enrolls-first-patient-fd419735b9f7a212Pharma Surgeen2026-08-01T06:43:05.000ZKeros Receives $20M Milestone as Elritercept Phase 3 Trial Enrolls First Patienthttps://www.pharmaradar360.com/article/moleculin-biotech-updates-annamycin-data-prices-stock-offering-at-0-75-2f2af2ff3ce3d85ePharma Surgeen2026-08-01T06:43:05.000ZMoleculin Biotech updates Annamycin data, prices stock offering at $0.75https://www.pharmaradar360.com/article/karyopharm-s-selinexor-misses-primary-endpoint-in-phase-3-endometrial-cancer-tri-9b67a3c9e033d152Pharma Surgeen2026-08-01T06:33:05.000ZKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trialhttps://www.pharmaradar360.com/article/china-recruits-105-top-us-scientists-as-biotech-race-intensifies-db017f09367672edPharma Surgeen2026-08-01T05:49:33.000ZChina recruits 105 top US scientists as biotech race intensifieshttps://www.pharmaradar360.com/article/why-drug-safety-has-become-india-s-next-pharmaceutical-imperative-fe7e802c10775113Pharma Surgeen2026-08-01T05:44:49.000ZWhy Drug Safety Has Become India's Next Pharmaceutical Imperativehttps://www.pharmaradar360.com/article/maharashtra-fda-crackdown-why-hotel-bodies-want-modi-fadnavis-to-step-in-a697389f247b3ba6Pharma Surgeen2026-08-01T05:12:17.000ZMaharashtra FDA crackdown: Why hotel bodies want Modi, Fadnavis to step inhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-veraxa-biotech-ag-nasdaq-vrxa-9e43d26d8df8d00fPharma Surgeen2026-08-01T04:35:00.000ZEnterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXAhttps://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-trading-up-0-2-time-to-buy-f2e9503f70550445Pharma Surgeen2026-08-01T04:32:07.000ZOncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy?https://www.pharmaradar360.com/article/create-medicines-expands-targeted-in-vivo-car-platform-through-strategic-researc-2d74a39b788189b5Pharma Surgeen2026-08-01T03:01:46.000ZCREATE medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license agreement with Monash Universityhttps://www.pharmaradar360.com/article/karnataka-to-ban-junk-food-around-schools-25ea1f750a5cc074Pharma Surgeen2026-08-01T02:30:53.000ZKarnataka to ban junk food around schoolshttps://www.pharmaradar360.com/article/daily-brief-health-care-moleculin-biotech-attovia-therapeutics-biostem-technolog-90829a4dcacff4c2Pharma Surgeen2026-08-01T02:02:05.000ZDaily Brief Health Care: Moleculin Biotech , Attovia Therapeutics, BioStem Technologies , Harbin Yuyantang Traditional Chinese Medicine Outpatient Group, Braveheart Bio, Vogenx, Apnimed and morehttps://www.pharmaradar360.com/article/ipo-databook-moleculin-biotech-mbrx-us-jul-2026-890a33dc59bc8dc3Pharma Surgeen2026-08-01T02:01:47.000ZIPO Databook: Moleculin Biotech (MBRX US) - Jul 2026https://www.pharmaradar360.com/article/price-to-sales-forward-of-samil-pharmaceutical-co-ltd-krx-000520-c223c21b3169a5a4Pharma Surgeen2026-08-01T01:54:35.000ZPrice to sales forward of Samil Pharmaceutical Co., Ltd. – KRX:000520https://www.pharmaradar360.com/article/blackrock-inc-trims-alumis-inc-alms-stake-amid-biotech-s-met-67744805cea9f09ePharma Surgeen2026-08-01T01:49:21.000ZBlackRock, Inc. Trims Alumis Inc (ALMS) Stake Amid Biotech's Methttps://www.pharmaradar360.com/article/novo-nordisk-misses-key-heart-outcomes-in-phase-3-shares-sink-10-chosunbiz-79aa02121ec86d9dPharma Surgeen2026-08-01T01:36:00.000ZNovo Nordisk misses key heart outcomes in Phase 3, shares sink 10% - CHOSUNBIZhttps://www.pharmaradar360.com/article/medicines-misleading-ads-on-tukaram-mundhe-s-radar-maharashtra-fda-chief-says-721c22f1278de122Pharma Surgeen2026-08-01T01:30:01.000ZMedicines, Misleading Ads On Tukaram Mundhe's Radar? Maharashtra FDA Chief Says...https://www.pharmaradar360.com/article/fda-panel-backs-unapproved-peptides-despite-safety-concerns-22833d81f60e2149Pharma Surgeen2026-08-01T01:06:08.000ZFDA panel backs unapproved peptides despite safety concernshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-raised-guidance-is-it-still-16-undervalued-028fc57a01f44af0Pharma Surgeen2026-08-01T00:43:41.000ZWest Pharmaceutical Services (WST) Raised Guidance, Is It Still 16% Undervalued?https://www.pharmaradar360.com/article/actinogen-medical-advances-pivotal-xanamia-trial-towards-november-readout-icymi-099bb910e9046a5fPharma Surgeen2026-08-01T00:00:33.000ZActinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMIhttps://www.pharmaradar360.com/article/sns-74c7f276908b05f6Pharma Surgeen2026-08-01T00:00:00.000Z当社名をかたるSNSなりすましアカウントに関する注意喚起https://www.pharmaradar360.com/article/2026-96578fb344d8a6a9Pharma Surgeen2026-08-01T00:00:00.000Z「健康経営優良法人2026（大規模法人部門）」に認定https://www.pharmaradar360.com/article/s-p-global-sustainability-yearbook-member-2026-958ba77733f54961Pharma Surgeen2026-08-01T00:00:00.000ZS&P GlobalによるSustainability Yearbook Member 2026に選定https://www.pharmaradar360.com/article/0-5-4eb57423dee8c7f8Pharma Surgeen2026-08-01T00:00:00.000Zアレルギー性結膜炎治療剤「アレジオン®眼瞼クリーム0.5%」参天製薬と杏林製薬の日本における共同販売促進契約締結のお知らせhttps://www.pharmaradar360.com/article/stn1012700-ryjusea-0-25mg-ml-dd0933d811da22d9Pharma Surgeen2026-08-01T00:00:00.000Z近視の進行抑制を目的とする点眼剤STN1012700（Ryjusea 0.25mg/mL点眼液）についてアジア事業地域で初めてとなる販売承認をフィリピンで取得https://www.pharmaradar360.com/article/0-02-6419f044f53442e2Pharma Surgeen2026-08-01T00:00:00.000Z緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得https://www.pharmaradar360.com/article/db0b80c339aa9269Pharma Surgeen2026-08-01T00:00:00.000Z「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―https://www.pharmaradar360.com/article/santen-5-4ca46a96459c42cdPharma Surgeen2026-08-01T00:00:00.000ZSanten中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結https://www.pharmaradar360.com/article/0-1-c58398bfb5224414Pharma Surgeen2026-08-01T00:00:00.000Z後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせhttps://www.pharmaradar360.com/article/05561923dc05a83aPharma Surgeen2026-08-01T00:00:00.000Z役員人事に関するお知らせhttps://www.pharmaradar360.com/article/8-b276e13c2c217314Pharma Surgeen2026-08-01T00:00:00.000Z＜花粉症に対する意識調査＞ 花粉症で「パフォーマンスに影響あり」は8割以上 「初期療法（早期治療）」を正しく知っている人の半数以上は「毎年実施」 ～眼科医と気象予報士が解説、花粉飛散期前の対策で春をより快適に～https://www.pharmaradar360.com/article/40-mg-ml-70160edfee675c11Pharma Surgeen2026-08-01T00:00:00.000Zアフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定についてhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dbfd7bd5fc9b705aPharma Surgeen2026-08-01T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-70a3022383a43852Pharma Surgeen2026-08-01T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-ad2b2d1099205a39Pharma Surgeen2026-08-01T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-007adc11b93de920Pharma Surgeen2026-08-01T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-bad3083242508c7aPharma Surgeen2026-08-01T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-55485bb313d1b727Pharma Surgeen2026-08-01T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-8f410dfa349e6391Pharma Surgeen2026-08-01T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-11d8fe59ddd38695Pharma Surgeen2026-08-01T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-26b59e55e1dd6926Pharma Surgeen2026-08-01T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-61a436e2e31c408aPharma Surgeen2026-08-01T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-ec9923c2f53a0879Pharma Surgeen2026-08-01T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-7d5625c9f1295b61Pharma Surgeen2026-08-01T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-288ee9984e7d3ad5Pharma Surgeen2026-08-01T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-0d8d081505fcf463Pharma Surgeen2026-08-01T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/2026-d377ede07642acf8Pharma Surgeen2026-08-01T00:00:00.000Z「2026年度 参天製薬奨学寄付プログラム」の募集は終了しましたhttps://www.pharmaradar360.com/article/refinement-of-operating-characteristics-for-model-based-tgi-metrics-decision-sup-95fbb815f42a5afdPharma Surgeen2026-08-01T00:00:00.000ZRefinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology.https://www.pharmaradar360.com/article/a-bayesian-optimal-adaptive-clinical-trial-design-for-sequentially-integrated-th-67de5d5e76bcd1c3Pharma Surgeen2026-08-01T00:00:00.000ZA Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.https://www.pharmaradar360.com/article/safety-tolerability-pharmacokinetics-food-effect-of-ribitol-and-its-effect-on-qt-87d288d261b77ab1Pharma Surgeen2026-08-01T00:00:00.000ZSafety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First-in-Human, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Studies.https://www.pharmaradar360.com/article/innovative-clinical-pharmacology-modeling-and-simulation-strategies-for-accelera-29ae1ba27af1eb12Pharma Surgeen2026-08-01T00:00:00.000ZInnovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development.https://www.pharmaradar360.com/article/ssgj-613-alleviates-pain-and-reduces-the-risk-of-acute-flares-in-patients-with-g-bbb3fff8f5f5eee6Pharma Surgeen2026-08-01T00:00:00.000ZSSGJ-613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double-Blind, Phase II Study.https://www.pharmaradar360.com/article/effects-of-bifidobacterium-animalis-subsp-lactis-cp-9-on-gut-microbiota-and-immu-cfe106e47cd7ae69Pharma Surgeen2026-08-01T00:00:00.000ZEffects of Bifidobacterium animalis Subsp. Lactis CP-9 on Gut Microbiota and Immune Functions in Healthy Infants.https://www.pharmaradar360.com/article/pragmatic-two-stage-design-for-clinical-trials-with-treatment-selection-1a007a55796c2579Pharma Surgeen2026-08-01T00:00:00.000ZPragmatic Two-Stage Design for Clinical Trials With Treatment Selection.https://www.pharmaradar360.com/article/a-simulation-based-assessment-of-dosage-regimen-appropriateness-for-multiple-mye-3267327c98fbdd93Pharma Surgeen2026-08-01T00:00:00.000ZA Simulation-Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences.https://www.pharmaradar360.com/article/pharmacological-insights-and-clinical-challenges-of-wenxin-keli-in-arrhythmia-tr-7d8e4073b4a6df28Pharma Surgeen2026-08-01T00:00:00.000ZPharmacological Insights and Clinical Challenges of Wenxin Keli in Arrhythmia Treatment.https://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-olamkicept-doses-up-to-2400-mg-in-healthy-japanes-6c7c213d60381fe3Pharma Surgeen2026-08-01T00:00:00.000ZSafety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.https://www.pharmaradar360.com/article/vobramitamab-duocarmazine-an-anti-b7-h3-antibody-drug-conjugate-in-patients-with-ba0cda32da4a1114Pharma Surgeen2026-08-01T00:00:00.000ZVobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.https://www.pharmaradar360.com/article/does-increasing-sample-size-inevitably-lead-to-statistical-significance-insights-3d2a138fb4013a78Pharma Surgeen2026-08-01T00:00:00.000ZDoes Increasing Sample Size Inevitably Lead to Statistical Significance? Insights From a Monte Carlo Simulation Study for Medical Research Design.https://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-olamkicept-5b651181281b131ePharma Surgeen2026-08-01T00:00:00.000ZSafety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.https://www.pharmaradar360.com/article/a-prospective-observational-study-of-anamorelin-during-chemoimmunotherapy-in-non-bbcbf572ba9f0f37Pharma Surgeen2026-08-01T00:00:00.000ZA Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).https://www.pharmaradar360.com/article/dexamethasone-versus-placebo-in-comatose-survivors-of-out-of-hospital-cardiac-ar-e823b43db5cad9b1Pharma Surgeen2026-08-01T00:00:00.000ZDexamethasone Versus Placebo in Comatose Survivors of Out-of-Hospital Cardiac Arrest: Study Protocol for a Multicenter Randomized Comparison Within the Danish Out-of-Hospital Cardiac Arrest Trial (DANOHCA).https://www.pharmaradar360.com/article/prophylactic-olanzapine-versus-placebo-in-comatose-survivors-of-out-of-hospital-296f3b16b0b9f5f1Pharma Surgeen2026-08-01T00:00:00.000ZProphylactic Olanzapine Versus Placebo in Comatose Survivors of Out-of-Hospital Cardiac Arrest: Protocol for a Multicenter Randomized Comparison Within the Danish Out-of-Hospital Cardiac Arrest (DANOHCA) Trial.https://www.pharmaradar360.com/article/to-cluster-or-not-to-cluster-a-comparison-of-approaches-to-targeting-type-2-diab-c74dcb977b7bf79aPharma Surgeen2026-08-01T00:00:00.000ZTo Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.https://www.pharmaradar360.com/article/weight-lowering-drugs-and-natural-female-fertility-a-systematic-review-and-meta-5fc1f96357007c58Pharma Surgeen2026-08-01T00:00:00.000ZWeight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.https://www.pharmaradar360.com/article/differential-effects-of-sevoflurane-versus-propofol-on-calmodulin-expression-in-d5dc2bddf2b8178ePharma Surgeen2026-08-01T00:00:00.000ZDifferential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.https://www.pharmaradar360.com/article/the-mechanisms-of-myricetin-and-quercetin-in-regulating-mirna-140-and-mmp-timp-s-80f58ace311997ffPharma Surgeen2026-08-01T00:00:00.000ZThe mechanisms of myricetin and quercetin in regulating miRNA-140 and MMP/TIMP signaling pathway in osteoarthritis treatment.https://www.pharmaradar360.com/article/efficacy-and-safety-of-gs1-144-a-novel-neurokinin-3-receptor-antagonist-for-mode-871d6d7bdf007ec0Pharma Surgeen2026-08-01T00:00:00.000ZEfficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.https://www.pharmaradar360.com/article/accelerating-the-clinical-translation-of-antibody-drug-conjugates-in-pancreatobi-3d327cde6825226aPharma Surgeen2026-08-01T00:00:00.000ZAccelerating the Clinical Translation of Antibody-Drug Conjugates in Pancreatobiliary Cancers: A Comprehensive Clinical Trial Landscape Analysis Based on the Trialtrove Clinical Intelligence Database.https://www.pharmaradar360.com/article/phenotype-variability-in-interstitial-cystitis-clinical-trial-recruitment-7402ce417d4e535dPharma Surgeen2026-08-01T00:00:00.000ZPhenotype Variability in Interstitial Cystitis Clinical Trial Recruitment.https://www.pharmaradar360.com/article/incidentally-detected-dual-feeder-pulmonary-arteriovenous-malformation-mimicking-716460167a36c735Pharma Surgeen2026-08-01T00:00:00.000ZIncidentally Detected Dual-feeder Pulmonary Arteriovenous Malformation Mimicking a Pulmonary Mass on CT: A Case Reporthttps://www.pharmaradar360.com/article/a-case-of-lupus-erythematosus-panniculitis-of-the-abdominal-wall-imagingcytopath-0ca288ca16b5353dPharma Surgeen2026-08-01T00:00:00.000ZA Case of Lupus Erythematosus Panniculitis of the Abdominal Wall: Imagingcytopathological Associationhttps://www.pharmaradar360.com/article/magnesium-sulphate-versus-fentanyl-as-an-adjuvant-to-levobupivacaine-in-ultrasou-991c187465bf89dePharma Surgeen2026-08-01T00:00:00.000ZMagnesium Sulphate versus Fentanyl as an Adjuvant to Levobupivacaine in Ultrasoundguided Supraclavicular Brachial Plexus Block: A Randomised Controlled Studyhttps://www.pharmaradar360.com/article/inflammatory-cytokines-autoantibodies-and-salivary-gland-function-in-sjogren-s-s-09bac3e5141a15bbPharma Surgeen2026-08-01T00:00:00.000ZInflammatory cytokines, autoantibodies and salivary gland function in Sjögren’s syndrome: Effects of T. wilfordii as Hook F medical wine and tripterygium glycosides tabletshttps://www.pharmaradar360.com/article/bullying-in-predicting-gelotophobia-fear-of-ridicule-among-obese-women-attending-93fc6203f0120da1Pharma Surgeen2026-08-01T00:00:00.000Zالاسهام النسبي لاضطراب صورة الجسم والتنمر في التنبؤ برهاب الجيلوتوفوبيا(رهاب السخرية) لدى البدينات المترددات على مراكز علاج السمنة (دراسة سيكومترية- كلينيكية) bullying in predicting gelotophobia (fear of ridicule) among obese women attending obesity treatment centers (psychometric-clinical study)https://www.pharmaradar360.com/article/hemodynamic-response-to-intubation-with-4-different-laryngoscopes-in-coronary-ar-84cd19f6bcac26afPharma Surgeen2026-08-01T00:00:00.000ZHemodynamic Response to Intubation With 4 Different Laryngoscopes in Coronary Artery Bypass Graft Surgery: A Randomized Trialhttps://www.pharmaradar360.com/article/questioning-child-and-adolescent-sex-abuse-victims-at-trial-a-gender-based-inves-8b0bb9b43760550dPharma Surgeen2026-08-01T00:00:00.000ZQuestioning child and adolescent sex abuse victims at trial: A gender-based investigation.https://www.pharmaradar360.com/article/effect-of-transcript-length-temperature-and-lyophilization-on-mrna-lipid-nanopar-541a0d69e0d6e975Pharma Surgeen2026-08-01T00:00:00.000ZEffect of transcript length, temperature, and lyophilization on mRNA-lipid nanoparticle stabilityhttps://www.pharmaradar360.com/article/immunogenicity-and-safety-of-papilloguard-4-the-first-quadrivalent-hpv-vaccine-c-f52e53ab14ca053cPharma Surgeen2026-08-01T00:00:00.000ZImmunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15–25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trialhttps://www.pharmaradar360.com/article/broad-spectrum-antibiotic-prophylaxis-for-pancreatoduodenectomy-assessment-of-ea-56e62fa6f085ac6bPharma Surgeen2026-08-01T00:00:00.000ZBroad-spectrum antibiotic prophylaxis for pancreatoduodenectomy: Assessment of early adoption of randomized trial datahttps://www.pharmaradar360.com/article/looking-through-the-cracks-vulnerabilities-and-deprivation-in-the-brazilian-open-a3da9c3a8cde477dPharma Surgeen2026-08-01T00:00:00.000ZLooking through the cracks: vulnerabilities and deprivation in the Brazilian open drug sceneshttps://www.pharmaradar360.com/article/pregnancy-outcomes-following-eslicarbazepine-acetate-exposure-in-women-with-epil-17540b732ac91704Pharma Surgeen2026-08-01T00:00:00.000ZPregnancy outcomes following Eslicarbazepine acetate exposure in women with epilepsy: A global safety database analysis from clinical development to 16 years of post-marketing experiencehttps://www.pharmaradar360.com/article/targeting-pulmonary-vascular-alveolar-coupling-in-bronchopulmonary-dysplasia-the-3c4891c36f0884daPharma Surgeen2026-08-01T00:00:00.000ZTargeting pulmonary vascular–alveolar coupling in bronchopulmonary dysplasia: Therapeutic mechanisms and translational prospects of extracellular vesicle-based drug deliveryhttps://www.pharmaradar360.com/article/how-health-professionals-navigate-diagnostic-uncertainty-in-clinical-practice-a-b0c09bbb5021e09bPharma Surgeen2026-08-01T00:00:00.000ZHow health professionals navigate diagnostic uncertainty in clinical practice: A rapid scoping reviewhttps://www.pharmaradar360.com/article/reframing-immunonutrition-evidence-in-clinical-practice-a-call-for-standardised-03147c3319573e27Pharma Surgeen2026-08-01T00:00:00.000ZReframing immunonutrition evidence in clinical practice: A call for standardised mechanistic and outcome measureshttps://www.pharmaradar360.com/article/metabolic-adherence-and-sustainability-outcomes-of-plant-based-low-carbohydrate-f90223f6e14afa35Pharma Surgeen2026-08-01T00:00:00.000ZMetabolic, adherence, and sustainability outcomes of plant-based low-carbohydrate and ketogenic diets: A systematic review of clinical evidencehttps://www.pharmaradar360.com/article/biomarker-testing-among-patients-with-nonsquamous-nsclc-across-three-time-period-b9c42ffdb01f46eaPharma Surgeen2026-08-01T00:00:00.000ZBiomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms—A Brief Reporthttps://www.pharmaradar360.com/article/letter-to-the-editor-re-clinical-prediction-modeling-of-baseline-differential-re-ab1b81b6ad3a37f2Pharma Surgeen2026-08-01T00:00:00.000ZLetter to the Editor re: "Clinical prediction modeling of baseline differential renal function based on ultrasound in congenital unilateral ureteropelvic junction obstruction"https://www.pharmaradar360.com/article/interdisciplinary-intervention-gain-vs-enhanced-usual-care-for-reducing-severe-p-4caaf24e9e3d94caPharma Surgeen2026-08-01T00:00:00.000ZInterdisciplinary intervention (GAIN) vs. enhanced usual care for reducing severe post-concussion symptoms in adults 2–4 months post-injury: A stepped wedge cluster randomised controlled trialhttps://www.pharmaradar360.com/article/neighborhood-socioeconomic-deprivation-is-associated-with-operative-spinal-neopl-d58f7763298eef95Pharma Surgeen2026-08-01T00:00:00.000ZNeighborhood socioeconomic deprivation is associated with operative spinal neoplasms: a cross-sectional analysis of 1,038 patientshttps://www.pharmaradar360.com/article/assessing-the-assessors-comparative-performance-of-frailty-and-nutritional-metri-dc9cc99c1c8ffeb5Pharma Surgeen2026-08-01T00:00:00.000ZAssessing the Assessors: Comparative performance of frailty and nutritional metrics in predicting 30-Day morbidity and mortality after cranial neurosurgeryhttps://www.pharmaradar360.com/article/multi-strain-clostridioides-difficile-infection-increased-detection-and-clinical-b452f7baf62e4465Pharma Surgeen2026-08-01T00:00:00.000ZMulti-strain Clostridioides difficile infection: Increased detection and clinical implicationshttps://www.pharmaradar360.com/article/0512-guselkumab-for-the-treatment-of-guttate-and-plaque-psoriasis-a-prospective-f481f4941991eed6Pharma Surgeen2026-08-01T00:00:00.000Z0512 Guselkumab for the treatment of guttate and plaque psoriasis: A prospective trialhttps://www.pharmaradar360.com/article/fabrication-and-characterization-of-buccal-dissolving-microneedles-for-the-poten-24fa7d3c25944765Pharma Surgeen2026-08-01T00:00:00.000ZFabrication and Characterization of buccal dissolving microneedles for the potential management of Parkinson Diseasehttps://www.pharmaradar360.com/article/recent-advances-on-thermoresponsive-hydrogels-in-ophthalmology-with-specific-foc-206930c9e14b4403Pharma Surgeen2026-08-01T00:00:00.000ZRecent advances on thermoresponsive hydrogels in ophthalmology with specific focus on their applications in dry eye disease management: Current status and future prospectivehttps://www.pharmaradar360.com/article/thyroid-cancer-and-double-strand-dna-break-repair-the-potential-role-of-the-mrn-af929dad9dfe97cbPharma Surgeen2026-08-01T00:00:00.000ZThyroid cancer and double-strand DNA break repair: The potential role of the MRN complex pathogenic variantshttps://www.pharmaradar360.com/article/letter-to-the-editor-clinical-outcomes-of-early-fast-compared-to-slow-sodium-cor-aeeec81d6df84f87Pharma Surgeen2026-08-01T00:00:00.000ZLetter to the editor: “Clinical outcomes of early fast compared to slow sodium correction rate in adults with severe hypernatremia: A comparative effectiveness study”https://www.pharmaradar360.com/article/impact-of-cyst-maturity-on-drug-resistance-assays-in-acanthamoeba-genotype-t4-bb76a0dbe2c86c0dPharma Surgeen2026-08-01T00:00:00.000ZImpact of cyst maturity on drug resistance assays in Acanthamoeba Genotype T4https://www.pharmaradar360.com/article/anaphalis-margaritacea-ethanol-extract-exhibits-potent-anti-trichinella-spiralis-53182496667167ebPharma Surgeen2026-08-01T00:00:00.000ZAnaphalis margaritacea ethanol extract exhibits potent anti-Trichinella spiralis activity via mitochondrial dysfunction and host tissue protectionhttps://www.pharmaradar360.com/article/postoperative-effects-of-horizontal-platelet-rich-fibrin-after-impacted-third-mo-cbbc81e203c54248Pharma Surgeen2026-08-01T00:00:00.000ZPostoperative effects of horizontal platelet-rich fibrin after impacted third molar extraction: a randomized controlled trialhttps://www.pharmaradar360.com/article/ion-valency-driven-control-of-network-architecture-and-tissue-level-drug-transpo-ef0dfe43ef5010f4Pharma Surgeen2026-08-01T00:00:00.000ZIon valency–driven control of network architecture and tissue-level drug transport in protein-derived hydrogelshttps://www.pharmaradar360.com/article/tlr4-knockout-ameliorates-acute-lps-sensitized-tolvaptan-induced-idiosyncratic-l-d1f8dade3d3c2da2Pharma Surgeen2026-08-01T00:00:00.000ZTLR4 knockout ameliorates acute LPS-sensitized tolvaptan-induced idiosyncratic liver injury by disrupting drug metabolism, inflammation, and bile acid homeostasishttps://www.pharmaradar360.com/article/cd20-targeted-immunotherapies-in-b-cell-malignancies-mechanistic-and-clinical-ad-98894e2eb88fa8aePharma Surgeen2026-08-01T00:00:00.000ZCD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advanceshttps://www.pharmaradar360.com/article/differences-in-reactive-metabolite-formation-and-cytochrome-p450-binding-between-b11bcef888756fcePharma Surgeen2026-08-01T00:00:00.000ZDifferences in reactive metabolite formation and cytochrome P450 binding between acetaminophen and its bicyclo[1.1.1]pentane bioisosterehttps://www.pharmaradar360.com/article/effects-of-different-exercise-modalities-and-doses-on-glycated-hemoglobin-in-pat-4df077c73f895635Pharma Surgeen2026-08-01T00:00:00.000ZEffects of different exercise modalities and doses on glycated hemoglobin in patients with type 2 diabetes mellitus and overweight or obesity: a systematic review and Bayesian multilevel network meta-analysishttps://www.pharmaradar360.com/article/prediabetes-in-ontario-improving-surveillance-for-better-disease-prevention-0b0a09f512e6fb48Pharma Surgeen2026-08-01T00:00:00.000ZPrediabetes in Ontario: improving surveillance for better disease preventionhttps://www.pharmaradar360.com/article/the-first-epidemiological-study-of-presymptomatic-type-1-diabetes-among-first-de-4ecb70e73204869fPharma Surgeen2026-08-01T00:00:00.000ZThe first epidemiological study of presymptomatic type 1 diabetes among first-degree relatives in Japan: PREP-T1D studyhttps://www.pharmaradar360.com/article/deep-learning-reconstruction-dual-energy-computed-tomography-for-gastrointestina-e4882da725ede1cdPharma Surgeen2026-08-01T00:00:00.000ZDeep learning reconstruction dual-energy computed tomography for gastrointestinal system tumors: low-kiloelectron volt imaging vs routine imaginghttps://www.pharmaradar360.com/article/prejudice-against-jagged-personality-profiles-rethinking-bias-in-psychological-r-701f102a64c81a8dPharma Surgeen2026-08-01T00:00:00.000ZPrejudice against jagged personality profiles: Rethinking bias in psychological research and clinical practicehttps://www.pharmaradar360.com/article/pharmaceutical-residues-as-emerging-contaminants-health-impacts-and-the-financia-bee473ea20cb4fb0Pharma Surgeen2026-08-01T00:00:00.000ZPharmaceutical residues as emerging contaminants: Health impacts and the financial burden of exposurehttps://www.pharmaradar360.com/article/risk-of-major-structural-birth-defects-following-repeat-mrna-covid-19-vaccinatio-556c78c6652d4737Pharma Surgeen2026-08-01T00:00:00.000ZRisk of major structural birth defects following repeat mRNA COVID-19 vaccination in the first trimester: a population-based cohort studyhttps://www.pharmaradar360.com/article/prognostic-value-of-the-geriatric-nutritional-risk-index-for-long-term-all-cause-5f076901580e68c2Pharma Surgeen2026-08-01T00:00:00.000ZPrognostic Value of the Geriatric Nutritional Risk Index for Long-Term All-Cause Mortality in Older Patients with Non-ST-Segment Elevation Myocardial Infarctionhttps://www.pharmaradar360.com/article/nutritional-prehabilitation-for-robot-assisted-radical-prostatectomy-a-proposed-7ca5e668204ad53fPharma Surgeen2026-08-01T00:00:00.000ZNutritional prehabilitation for robot-assisted radical prostatectomy: A proposed clinical framework integrating body composition analysishttps://www.pharmaradar360.com/article/medium-chain-triglyceride-supplementation-in-preterm-infants-a-prospective-cohor-206c83f8e0e7be79Pharma Surgeen2026-08-01T00:00:00.000ZMedium-chain triglyceride supplementation in preterm infants: A prospective cohort studyhttps://www.pharmaradar360.com/article/resting-state-eeg-for-continuous-prognostic-monitoring-and-prediction-of-coma-re-0f494b9c32f51545Pharma Surgeen2026-08-01T00:00:00.000ZResting-state EEG for continuous prognostic monitoring and prediction of coma recovery after acute brain injuryhttps://www.pharmaradar360.com/article/video-oculography-derived-oculomotor-indices-in-parkinson-s-disease-methodologic-f8595d6546ec9a73Pharma Surgeen2026-08-01T00:00:00.000ZVideo-oculography-derived oculomotor indices in Parkinson’s disease: Methodological limitations restrict clinical translationhttps://www.pharmaradar360.com/article/natural-history-and-radiological-features-of-rathke-s-cleft-cysts-diagnosed-on-m-365c4a11f4160e4bPharma Surgeen2026-08-01T00:00:00.000ZNatural history and radiological features of Rathke’s cleft cysts diagnosed on MRI: Analysis of 410 patients including 279 managed conservativelyhttps://www.pharmaradar360.com/article/safety-of-continuing-antithrombotic-therapy-during-lumboperitoneal-shunting-for-28cc2f907f5813bfPharma Surgeen2026-08-01T00:00:00.000ZSafety of continuing antithrombotic therapy during lumboperitoneal shunting for idiopathic normal pressure hydrocephalus: A single-center retrospective analysishttps://www.pharmaradar360.com/article/mri-assessed-small-vessel-disease-burden-and-gait-performance-in-post-ischemic-s-09147a9a1f8f6241Pharma Surgeen2026-08-01T00:00:00.000ZMRI-assessed small vessel disease burden and gait performance in post-ischemic stroke hemiparesishttps://www.pharmaradar360.com/article/when-findings-hurt-mental-health-effects-of-cerebral-mri-screening-in-patients-w-100222f99e1d3d95Pharma Surgeen2026-08-01T00:00:00.000ZWhen findings hurt: Mental health effects of cerebral MRI screening in patients with Hereditary Hemorrhagic Telangiectasiahttps://www.pharmaradar360.com/article/chronic-kidney-disease-does-not-influence-response-to-terlipressin-in-hepatorena-172043990c2c3e07Pharma Surgeen2026-08-01T00:00:00.000ZChronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injuryhttps://www.pharmaradar360.com/article/ai-assisted-capsule-endoscopy-for-detection-of-ulcers-and-erosions-in-crohn-s-di-9c39a67ef3c8cc09Pharma Surgeen2026-08-01T00:00:00.000ZAI-Assisted Capsule Endoscopy for Detection of Ulcers and Erosions in Crohn’s Disease: A Multicenter Validation Studyhttps://www.pharmaradar360.com/article/fecal-microbiota-based-therapies-compared-to-fecal-microbiota-transplantation-fo-617e082daf2a0ac4Pharma Surgeen2026-08-01T00:00:00.000ZFecal Microbiota-Based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C difficile Infectionhttps://www.pharmaradar360.com/article/multi-omics-biomarker-in-adrenocortical-carcinoma-a-clinical-chemistry-perspecti-ae02eedc1e89a100Pharma Surgeen2026-08-01T00:00:00.000ZMulti-omics biomarker in adrenocortical carcinoma: a clinical-chemistry perspectivehttps://www.pharmaradar360.com/article/deep-learning-framework-integrating-18f-fdg-pet-ct-and-clinical-data-for-early-p-148680b759ced19cPharma Surgeen2026-08-01T00:00:00.000ZDeep learning framework integrating 18F-FDG PET/CT and clinical data for early prediction of chemotherapy response in advanced breast cancerhttps://www.pharmaradar360.com/article/the-impact-of-food-advertising-on-children-s-daily-energy-intake-does-it-differ-e033c1f1e698fc6bPharma Surgeen2026-08-01T00:00:00.000ZThe impact of food advertising on children's daily energy intake: does it differ by advertising content, format, or participant characteristics? A cross-over randomised controlled trialhttps://www.pharmaradar360.com/article/emotions-documented-in-clinical-notes-an-interpretative-descriptive-study-b3aa88fc37d21b1dPharma Surgeen2026-08-01T00:00:00.000ZEmotions documented in clinical notes: An interpretative descriptive studyhttps://www.pharmaradar360.com/article/magnesium-sulfate-for-neuroprotection-approach-to-addressing-clinical-questions-60fe57492e860c25Pharma Surgeen2026-08-01T00:00:00.000ZMagnesium sulfate for neuroprotection: Approach to addressing clinical questionshttps://www.pharmaradar360.com/article/rethinking-the-impact-of-dietary-sodium-and-potassium-on-blood-pressure-to-advan-dd995e44325964cdPharma Surgeen2026-08-01T00:00:00.000ZRethinking the impact of dietary sodium and potassium on blood pressure to advance public healthhttps://www.pharmaradar360.com/article/development-and-clinical-validation-of-a-protocol-agnostic-machine-learning-plat-e9d7a1ba7fbd899cPharma Surgeen2026-08-01T00:00:00.000ZDevelopment and Clinical Validation of a Protocol-Agnostic Machine Learning Platform for Automated Treatment Planning in External Beam Radiation Therapyhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-2026-q2-results-earnings-call-presentatio-2d987125eebfb023Pharma Surgeen2026-07-31T23:09:47.000ZTeva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation (NYSE:TEVA) 2026-07-31https://www.pharmaradar360.com/article/zhejiang-tianyu-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300702-50300990cfba0914Pharma Surgeen2026-07-31T22:13:59.000ZZhejiang Tianyu Pharmaceutical Co. Ltd. Class A Revenue Breakdown – SZSE:300702https://www.pharmaradar360.com/article/epi-biotech-co-ltd-revenue-breakdown-krx-446440-d2fcd77bdd048a51Pharma Surgeen2026-07-31T22:10:55.000ZEpi Biotech Co., Ltd. Revenue Breakdown – KRX:446440https://www.pharmaradar360.com/article/j-j-s-biotech-progress-could-punish-its-2027-profit-79a0c143ed981ccaPharma Surgeen2026-07-31T22:03:00.000ZJ&J’s biotech progress could punish its 2027 profithttps://www.pharmaradar360.com/article/ipo-news-he-mei-pharmaceutical-s-hong-kong-ipo-and-full-convertibility-of-its-do-e0eafefa7ae5dfbfPharma Surgeen2026-07-31T21:56:23.000ZIPO News | He Mei Pharmaceutical's Hong Kong IPO and full convertibility of its domestically held unlisted shares have received filing confirmation from the China Securities Regulatory Commission (CSRC).https://www.pharmaradar360.com/article/krystal-biotech-slides-as-investors-appear-to-reset-ahead-of-earnings-6846453b5dcc5ad3Pharma Surgeen2026-07-31T21:26:00.000ZKrystal Biotech slides as investors appear to reset ahead of earningshttps://www.pharmaradar360.com/article/medipharco-pharmaceutical-joint-stock-co-revenue-breakdown-upcom-mtp-99a788dc776f2cb9Pharma Surgeen2026-07-31T21:24:02.000ZMedipharco Pharmaceutical Joint Stock Co Revenue Breakdown – UPCOM:MTPhttps://www.pharmaradar360.com/article/why-breakthrough-therapies-in-biotech-are-losing-the-commercial-battle-98c97abfb4d27d8cPharma Surgeen2026-07-31T21:23:00.000ZWhy Breakthrough Therapies in Biotech Are Losing the Commercial Battlehttps://www.pharmaradar360.com/article/northeast-pharmaceutical-group-co-ltd-class-a-revenue-breakdown-szse-000597-88b0e1247effc29bPharma Surgeen2026-07-31T21:20:59.000ZNortheast Pharmaceutical Group Co., Ltd. Class A Revenue Breakdown – SZSE:000597https://www.pharmaradar360.com/article/novo-drug-trial-fail-deals-setback-to-bid-to-expand-beyond-obesity-cf43caf683c83fe4Pharma Surgeen2026-07-31T21:20:13.000ZNovo drug trial fail deals setback to bid to expand beyond obesityhttps://www.pharmaradar360.com/article/veraxa-biotech-holding-ag-files-to-register-resale-of-up-to-25-million-ordinary-c9341ed92547762cPharma Surgeen2026-07-31T21:19:46.000ZVeraxa Biotech Holding AG - Files To Register Resale Of Up To 25 Million Ordinary Shares - SEC Filinghttps://www.pharmaradar360.com/article/novo-nordisk-shares-plunge-after-a-key-trial-fails-should-investors-buy-the-dip-cba0c4f4dc953657Pharma Surgeen2026-07-31T21:15:09.000ZNovo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?https://www.pharmaradar360.com/article/rock-hill-inks-1-5b-investment-deal-with-pharmaceutical-company-for-former-panth-8018ee46d6537031Pharma Surgeen2026-07-31T20:59:25.000ZRock Hill inks $1.5B investment deal with pharmaceutical company for former Panthers sitehttps://www.pharmaradar360.com/article/spartanburg-pharmaceutical-facility-to-close-layoff-nearly-200-employees-f2bce11cc64d3ed3Pharma Surgeen2026-07-31T20:50:00.000ZSpartanburg pharmaceutical facility to close, layoff nearly 200 employeeshttps://www.pharmaradar360.com/article/the-hiv-shot-that-could-change-medicine-is-facing-its-biggest-test-getting-to-pa-9d0f1402dc628284Pharma Surgeen2026-07-31T20:43:00.000ZThe HIV shot that could change medicine is facing its biggest test: Getting to patientshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-guangzhou-wondfo-biotech-co-ltd-class-a-szse-300482-73ca3b85ca0bf823Pharma Surgeen2026-07-31T20:39:22.000ZPrice to earnings forward of Guangzhou Wondfo Biotech Co., Ltd. Class A – SZSE:300482https://www.pharmaradar360.com/article/price-to-sales-forward-of-guangzhou-wondfo-biotech-co-ltd-class-a-szse-300482-98becf2f1e9640fcPharma Surgeen2026-07-31T20:38:24.000ZPrice to sales forward of Guangzhou Wondfo Biotech Co., Ltd. Class A – SZSE:300482https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-guangzhou-wondfo-biotech-co-ltd-class-a-sz-1e19f756b6085056Pharma Surgeen2026-07-31T20:34:55.000ZEnterprise value to EBITDA forward of Guangzhou Wondfo Biotech Co., Ltd. Class A – SZSE:300482https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-sichuan-biokin-pharmaceutical-co-ltd-class-a-133f0b0d5189d136Pharma Surgeen2026-07-31T20:30:20.000ZEnterprise value to EBIT forward of Sichuan Biokin Pharmaceutical Co., Ltd. Class A – SSE:688506https://www.pharmaradar360.com/article/biotech-ceo-explains-how-his-company-is-using-ai-to-detect-cancer-0f7e2e417c3de646Pharma Surgeen2026-07-31T20:28:26.000ZBiotech CEO explains how his company is using AI to detect cancerhttps://www.pharmaradar360.com/article/this-biotech-stock-soars-107-after-key-fda-panel-vote-on-skin-cancer-treatment-387d85c0a75182dcPharma Surgeen2026-07-31T20:22:00.000ZThis Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatmenthttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-grows-patent-estate-for-bitac-cancer-platforms-817df9790edf6a75Pharma Surgeen2026-07-31T20:05:41.000ZVeraxa Biotech (VRXA) grows patent estate for BiTAC cancer platformshttps://www.pharmaradar360.com/article/regulatory-roundup-july-2026-edea80f657029eefPharma Surgeen2026-07-31T19:47:22.000ZRegulatory Roundup—July 2026https://www.pharmaradar360.com/article/fda-weighs-in-on-peptides-va-tests-new-use-for-popular-drug-and-wildfire-smoke-r-7cf019049c4fd0e8Pharma Surgeen2026-07-31T19:41:00.000ZFDA weighs in on peptides, VA tests new use for popular drug and wildfire smoke returnshttps://www.pharmaradar360.com/article/biotech-stocks-facing-fda-decision-in-august-2026-398ba9987c541238Pharma Surgeen2026-07-31T18:55:34.000ZBiotech Stocks Facing FDA Decision In August 2026https://www.pharmaradar360.com/article/premature-menopause-increases-risk-of-high-blood-pressure-study-finds-647d2648b450b719Pharma Surgeen2026-07-31T18:50:37.000ZPremature menopause increases risk of high blood pressure, study findshttps://www.pharmaradar360.com/article/icbs-funded-for-independent-prescribing-implementation-0020c9f25027c7b0Pharma Surgeen2026-07-31T18:50:37.000ZICBs funded for independent prescribing implementationhttps://www.pharmaradar360.com/article/who-begins-trial-for-ebola-outbreak-a93ef5c66e1a533fPharma Surgeen2026-07-31T18:45:00.000ZWHO Begins Trial for Ebola Outbreakhttps://www.pharmaradar360.com/article/c16-biosciences-builds-palm-free-beauty-toolkit-with-biotech-ingredient-trio-1b508dcc07634583Pharma Surgeen2026-07-31T18:20:14.000ZC16 Biosciences builds palm-free beauty toolkit with biotech ingredient triohttps://www.pharmaradar360.com/article/johnson-johnson-shares-edge-higher-as-3-5b-biotech-moves-expand-oncology-pipelin-2b10b28a6c127f3bPharma Surgeen2026-07-31T18:19:45.000ZJohnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipelinehttps://www.pharmaradar360.com/article/psychedelics-gain-momentum-in-big-pharma-4dad0a0ba81fb1cbPharma Surgeen2026-07-31T18:05:00.000ZPsychedelics Gain Momentum in Big Pharmahttps://www.pharmaradar360.com/article/sweat-proof-wearable-sensors-offer-better-health-tracking-ceba4fe1b2fbd5ccPharma Surgeen2026-07-31T17:55:00.000ZSweat-Proof Wearable Sensors Offer Better Health Trackinghttps://www.pharmaradar360.com/article/moleculin-biotech-stock-is-sinking-friday-what-s-going-on-01b5e1239b8f6595Pharma Surgeen2026-07-31T17:37:09.000ZMoleculin Biotech Stock Is Sinking Friday: What's Going On?https://www.pharmaradar360.com/article/lanzamiento-de-la-app-doctorsv-para-atencion-medica-virtual-82e7c38c99ebbeddPharma Surgeen2026-07-31T17:28:11.000ZLanzamiento de la app DoctorSV para atención médica virtualhttps://www.pharmaradar360.com/article/fda-votes-10-to-3-in-favor-of-replimune-s-rp1-efficacy-data-pharmexec-a494b3919f726b2aPharma Surgeen2026-07-31T17:27:09.000ZFDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data | PharmExechttps://www.pharmaradar360.com/article/sublingual-semaglutide-offered-to-uk-practices-despite-novo-nordisk-concerns-b16b8dac1f5973acPharma Surgeen2026-07-31T17:20:57.000ZSublingual semaglutide offered to UK practices despite Novo Nordisk concernshttps://www.pharmaradar360.com/article/fda-tentative-approval-for-omcazio-a-new-cabozantinib-capsule-formulation-59801c1606dceb2fPharma Surgeen2026-07-31T17:18:13.000ZFDA Tentative Approval for Omcazio: A New Cabozantinib Capsule Formulationhttps://www.pharmaradar360.com/article/acto-de-juramentacion-de-nuevos-miembros-del-consejo-directivo-y-junta-de-vigila-8bb3f0677c2b20bePharma Surgeen2026-07-31T16:59:19.000ZActo de juramentación de nuevos miembros del Consejo Directivo y Junta de Vigilanciashttps://www.pharmaradar360.com/article/fda-clears-autoinjector-drug-for-home-treatment-of-heart-failure-edema-bf04e862fac670d3Pharma Surgeen2026-07-31T16:55:43.000ZFDA clears autoinjector drug for home treatment of heart failure edemahttps://www.pharmaradar360.com/article/krystal-biotech-drops-5-9-amid-sector-wide-selling-8b4a5e12bc34e0ecPharma Surgeen2026-07-31T16:34:24.000ZKrystal Biotech Drops 5.9% Amid Sector-Wide Sellinghttps://www.pharmaradar360.com/article/iova-stock-slides-as-biotech-traders-watch-key-support-f36ffcc98d99ad25Pharma Surgeen2026-07-31T16:32:00.000ZIOVA Stock Slides As Biotech Traders Watch Key Supporthttps://www.pharmaradar360.com/article/biotech-is-back-a-wave-of-life-science-deals-is-pumping-cash-into-the-sector-a7acd535ecafb0f5Pharma Surgeen2026-07-31T16:17:17.000ZBiotech is Back: A Wave of Life Science Deals is Pumping Cash into the Sectorhttps://www.pharmaradar360.com/article/why-onshoring-alone-won-t-secure-pharma-supply-chains-daf751411de5a6a6Pharma Surgeen2026-07-31T16:16:31.000ZWhy Onshoring Alone Won't Secure Pharma Supply Chainshttps://www.pharmaradar360.com/article/taisho-pharmaceutical-licenses-kaigene-s-kg006-for-japan-autoimmune-drug-push-25611fe319b223d8Pharma Surgeen2026-07-31T16:15:29.000ZTaisho Pharmaceutical licenses Kaigene’s KG006 for Japan autoimmune drug pushhttps://www.pharmaradar360.com/article/george-mason-licenses-cancer-imaging-technology-to-biotech-company-8dbdaf65a23a1ecbPharma Surgeen2026-07-31T16:08:22.000ZGeorge Mason licenses cancer imaging technology to biotech companyhttps://www.pharmaradar360.com/article/this-week-in-boomtown-aviation-industry-in-ohio-affordable-housing-future-of-bio-51d5297eeb42b45bPharma Surgeen2026-07-31T15:59:00.000ZThis Week in Boomtown: Aviation industry in Ohio; affordable housing; future of biotechhttps://www.pharmaradar360.com/article/sleep-apnea-biotech-apnimed-shares-jump-after-upsized-us-ipo-165c2614f7cdca45Pharma Surgeen2026-07-31T15:50:14.000ZSleep-Apnea Biotech Apnimed Shares Jump After Upsized US IPOhttps://www.pharmaradar360.com/article/novo-s-il-6-inhibitor-fails-in-cardiovascular-phase-3-plunging-shares-more-than-d45c13ddf2fc2cc5Pharma Surgeen2026-07-31T15:27:37.000ZNovo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%https://www.pharmaradar360.com/article/the-west-must-confront-china-s-biotech-offensive-e24e1804175ec2ffPharma Surgeen2026-07-31T15:26:26.000ZThe West Must Confront China’s Biotech Offensivehttps://www.pharmaradar360.com/article/biotech-produces-ebola-proteins-in-just-15-days-as-african-outbreak-intensifies-f8ce310d6a2d01c7Pharma Surgeen2026-07-31T15:25:36.000ZBiotech Produces Ebola Proteins in Just 15 Days as African Outbreak Intensifieshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-protect-pharmaceutical-corp-otc-prtt-212f652dae56100bPharma Surgeen2026-07-31T15:19:13.000ZPrice to earnings forward of Protect Pharmaceutical Corp – OTC:PRTThttps://www.pharmaradar360.com/article/weekly-buzz-cipla-vtrs-win-fda-nod-bsx-cuts-jobs-argx-snaps-up-fbrx-jnj-gsk-stri-b140a34fac9444cePharma Surgeen2026-07-31T14:51:00.000ZWeekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Dealshttps://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-31T14:47:36.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/novo-nordisk-shares-drop-after-drug-candidate-fails-in-trial-b758367c05ecb619Pharma Surgeen2026-07-31T14:40:00.000ZNovo Nordisk Shares Drop After Drug Candidate Fails in Trialhttps://www.pharmaradar360.com/article/milind-deora-urges-fssai-to-replicate-tukaram-mundhe-led-maharashtra-fda-s-crack-87a5fccb0e5d27d9Pharma Surgeen2026-07-31T14:39:16.000ZMilind Deora Urges FSSAI To Replicate Tukaram Mundhe-Led Maharashtra FDA's Crackdown Nationwide; Here's Whyhttps://www.pharmaradar360.com/article/silicon-valley-looks-to-a-new-biotech-frontier-montana-e61575a238363bddPharma Surgeen2026-07-31T14:36:00.000ZSilicon Valley Looks to a New Biotech Frontier: Montanahttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-1b10eeb5524e0803Pharma Surgeen2026-07-31T14:32:17.000ZUK Clinical Research Delivery key performance indicators: data to August 2026https://www.pharmaradar360.com/article/it-s-a-peptide-wild-west-how-rfk-jr-is-clearing-way-for-a-market-of-untested-dru-46ade855ec6c0d7dPharma Surgeen2026-07-31T14:32:00.000Z‘It’s a peptide wild west’: how RFK Jr is clearing way for a market of untested drugshttps://www.pharmaradar360.com/article/acute-kidney-injury-causes-diagnosis-and-management-fa7cafeb9e7d0398Pharma Surgeen2026-07-31T14:28:32.000ZAcute kidney injury: causes, diagnosis and managementhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-4-0ad4e689b0a5ba3fPharma Surgeen2026-07-31T14:20:25.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.46, Implies 13% Upsidehttps://www.pharmaradar360.com/article/moleculin-biotech-prices-9-3-million-best-efforts-public-offering-with-warrants-3fdb6773408ee09aPharma Surgeen2026-07-31T14:20:00.000ZMoleculin Biotech Prices $9.3 Million Best-Efforts Public Offering with Warrantshttps://www.pharmaradar360.com/article/moleculin-biotech-prices-9-3-million-public-offering-9dc6327d4e2e421fPharma Surgeen2026-07-31T14:19:46.000ZMoleculin Biotech prices $9.3 million public offeringhttps://www.pharmaradar360.com/article/appeals-court-says-iowa-vape-law-does-not-conflict-with-fda-rules-a578526bea3ed8c4Pharma Surgeen2026-07-31T14:16:00.000ZAppeals court says Iowa vape law does not conflict with FDA ruleshttps://www.pharmaradar360.com/article/malaria-prevention-guidelines-for-travellers-from-the-uk-2026-bfdb8582fd85690ePharma Surgeen2026-07-31T14:00:56.000ZMalaria prevention guidelines for travellers from the UK 2026https://www.pharmaradar360.com/article/xpovio-mulligan-in-endometrial-cancer-comes-up-short-as-karyopharm-presses-on-in-96dbc27633495848Pharma Surgeen2026-07-31T14:00:00.000ZXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosishttps://www.pharmaradar360.com/article/krystal-biotech-earnings-in-focus-as-vyjuvek-expansion-accelerates-bd43ca270a6d2d15Pharma Surgeen2026-07-31T13:58:00.000ZKrystal Biotech earnings in focus as Vyjuvek expansion accelerateshttps://www.pharmaradar360.com/article/vanguard-capital-management-coll-discloses-5-01-passive-stake-in-collegium-15f64aa947d7d558Pharma Surgeen2026-07-31T13:55:21.000ZVanguard Capital Management (COLL) discloses 5.01% passive stake in Collegiumhttps://www.pharmaradar360.com/article/government-takes-action-to-crack-down-on-rogue-funeral-operators-d91be37e803eb3b6Pharma Surgeen2026-07-31T13:39:25.000ZGovernment takes action to crack down on rogue funeral operatorshttps://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-a-novo-setback-support-for-replimune-s-melanoma-b7c10857584658a6Pharma Surgeen2026-07-31T13:30:31.000ZPharmalittle: We're reading about a Novo setback, support for Replimune's melanoma drug, and morehttps://www.pharmaradar360.com/article/biotech-stocks-facing-fda-decision-in-august-2026-713c235e44d8ba49Pharma Surgeen2026-07-31T13:13:00.000ZBiotech Stocks Facing FDA Decision In August 2026https://www.pharmaradar360.com/article/renaissance-wages-war-on-wireworms-in-new-challenge-for-targeted-biotech-c484c1b25b56c844Pharma Surgeen2026-07-31T13:11:37.000ZRenaissance Wages War on Wireworms in New Challenge for Targeted Biotechhttps://www.pharmaradar360.com/article/moleculin-biotech-mbrx-reports-preliminary-phase-2-3-trial-dat-ea8709bc2a49a7fbPharma Surgeen2026-07-31T13:09:20.000ZMoleculin Biotech (MBRX) Reports Preliminary Phase 2/3 Trial Dathttps://www.pharmaradar360.com/article/maharashtra-food-safety-crackdown-faces-legal-backlash-and-industry-opposition-33c4443cb9036487Pharma Surgeen2026-07-31T13:07:34.000ZMaharashtra Food Safety Crackdown Faces Legal Backlash and Industry Oppositionhttps://www.pharmaradar360.com/article/fierce-pharma-asia-legend-ceo-exits-merck-s-hush-hush-pd-1xvegf-plan-otsuka-s-no-94b8841a996fb9bePharma Surgeen2026-07-31T13:00:00.000ZFierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nodhttps://www.pharmaradar360.com/article/pfizer-s-litfulo-clears-two-phase-3-vitiligo-trials-paving-way-for-global-regula-85f0ddac8593a507Pharma Surgeen2026-07-31T13:00:00.000ZPfizer’s LITFULO clears two Phase 3 vitiligo trials paving way for global regulatory filingshttps://www.pharmaradar360.com/article/novo-nordisk-left-praying-to-artemis-and-hermes-to-salvage-ckd-program-after-pha-31e8f78d14e0fcd3Pharma Surgeen2026-07-31T12:57:34.000ZNovo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 failhttps://www.pharmaradar360.com/article/novo-nordisk-ziltivekimab-heart-drug-fails-phase-3-trial-4d98508182d418d1Pharma Surgeen2026-07-31T12:46:33.000ZNovo Nordisk ziltivekimab heart drug fails phase 3 trialhttps://www.pharmaradar360.com/article/novo-nordisk-ziltivekimab-heart-drug-fails-phase-3-trial-650564f8d6a4717fPharma Surgeen2026-07-31T12:46:15.000ZNovo Nordisk ziltivekimab heart drug fails phase 3 trialhttps://www.pharmaradar360.com/article/kaigene-maps-final-territory-for-kg006-with-taisho-deal-embedding-japan-partner-8999763d76338dbfPharma Surgeen2026-07-31T12:34:09.000ZKaigene maps final territory for KG006 with Taisho deal, embedding Japan partner in global Phase III trialhttps://www.pharmaradar360.com/article/novo-nordisk-plunges-10-percent-after-cardiovascular-drug-fails-trial-81bd63d306d60aeePharma Surgeen2026-07-31T12:32:46.000ZNovo Nordisk Plunges 10 Percent After Cardiovascular Drug Fails Trialhttps://www.pharmaradar360.com/article/cdsco-flags-159-substandard-drug-samples-as-nsq-including-14-linked-to-maharasht-7c95bef7799cd4d3Pharma Surgeen2026-07-31T12:32:28.000ZCDSCO Flags 159 Substandard Drug Samples As NSQ, Including 14 Linked To Maharashtrahttps://www.pharmaradar360.com/article/legend-ceo-departs-without-successor-in-place-chutes-ladders-f0a93415ee4b72b5Pharma Surgeen2026-07-31T12:29:45.000ZLegend CEO departs without successor in place—Chutes & Laddershttps://www.pharmaradar360.com/article/novo-nordisk-shakes-markets-as-ziltivekimab-fails-cardiovascular-trial-83bfbb44738e1d77Pharma Surgeen2026-07-31T12:14:55.000ZNovo Nordisk Shakes Markets as Ziltivekimab Fails Cardiovascular Trialhttps://www.pharmaradar360.com/article/we-are-in-india-we-have-to-take-a-realistic-stand-bombay-high-court-quashes-fda-be5b519e84b02901Pharma Surgeen2026-07-31T12:02:01.000Z‘We Are in India, We Have To Take a Realistic Stand’: Bombay High Court Quashes FDA Action Against Parkhttps://www.pharmaradar360.com/article/childhood-vaccination-coverage-provisional-monthly-data-for-england-096cd364d32970b8Pharma Surgeen2026-07-31T12:00:05.000ZChildhood vaccination coverage: provisional monthly data for Englandhttps://www.pharmaradar360.com/article/from-abu-dhabi-to-brazil-every-region-is-vying-for-the-new-emerging-economy-of-b-6f2a1e7ee617add0Pharma Surgeen2026-07-31T12:00:00.000ZFrom Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotechhttps://www.pharmaradar360.com/article/handa-oncology-receives-fda-tentative-approval-for-omcazio-cabozantinib-capsules-7ba5c07197e96f2dPharma Surgeen2026-07-31T12:00:00.000ZHanda Oncology Receives FDA Tentative Approval for OMCAZIO (cabozantinib) Capsuleshttps://www.pharmaradar360.com/article/spartanburg-pharmaceutical-facility-to-close-layoff-nearly-200-employees-d60dc531afefc33fPharma Surgeen2026-07-31T11:59:00.000ZSpartanburg pharmaceutical facility to close, layoff nearly 200 employeeshttps://www.pharmaradar360.com/article/abbvie-nyse-abbv-boosts-q2-profit-plans-10-9b-apogee-acquisition-94e22076c79befc5Pharma Surgeen2026-07-31T11:51:57.000ZAbbVie (NYSE: ABBV) boosts Q2 profit, plans $10.9B Apogee acquisitionhttps://www.pharmaradar360.com/article/abbvie-reports-second-quarter-2026-financial-results-d9247dc287bfbdcfPharma Surgeen2026-07-31T11:47:00.000ZAbbVie Reports Second-Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/abbvie-reports-second-quarter-2026-financial-results-94cce4f303cb088aPharma Surgeen2026-07-31T11:47:00.000ZAbbVie Reports Second-Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/fda-says-mantralaya-canteen-98-clean-bombay-high-court-orders-lawyers-inspection-144fb601297e148fPharma Surgeen2026-07-31T11:39:35.000ZFDA says Mantralaya canteen 98% clean, Bombay High Court orders lawyers' inspectionhttps://www.pharmaradar360.com/article/biogen-is-scaling-back-acquisitions-and-will-focus-on-its-existing-pipeline-26eda5ded5bafdadPharma Surgeen2026-07-31T11:33:38.000ZBiogen is scaling back acquisitions and will focus on its existing pipelinehttps://www.pharmaradar360.com/article/tenax-therapeutics-reports-q2-net-loss-17-8m-cash-118-0m-level-phase-3-topline-d-a601578f6359503aPharma Surgeen2026-07-31T11:33:00.000ZTenax Therapeutics reports Q2 net loss $17.8M, cash $118.0M; LEVEL Phase 3 topline due Aug 2026https://www.pharmaradar360.com/article/2026-99c693c59e5ca28aPharma Surgeen2026-07-31T11:30:00.000Z日本新薬レポート2026 発刊のお知らせhttps://www.pharmaradar360.com/article/2024-vpag-operational-review-minutes-e2c17cfb6d1983fcPharma Surgeen2026-07-31T11:27:45.000Z2024 VPAG operational review minuteshttps://www.pharmaradar360.com/article/2024-vpag-operational-review-12-august-2025-b4785a30a0d04a7cPharma Surgeen2026-07-31T11:27:36.000Z2024 VPAG operational review: 12 August 2025https://www.pharmaradar360.com/article/warsaw-s-world-first-liver-transplant-puts-eu-biotech-rules-in-the-spotlight-349c167b3d37d4c1Pharma Surgeen2026-07-31T11:23:16.000ZWarsaw’s world-first liver transplant puts EU biotech rules in the spotlighthttps://www.pharmaradar360.com/article/tenax-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-f3e66e55627d0589Pharma Surgeen2026-07-31T11:20:57.000ZTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/ziltivekimab-lowered-inflammation-markers-not-major-heart-events-b1f57f54308644f4Pharma Surgeen2026-07-31T11:20:00.000ZZiltivekimab lowered inflammation markers, not major heart eventshttps://www.pharmaradar360.com/article/vogenx-targets-modest-nasdaq-ipo-to-back-metabolic-drug-fb4f0be0bad0ce73Pharma Surgeen2026-07-31T11:14:44.000ZVogenx targets modest Nasdaq IPO to back metabolic drughttps://www.pharmaradar360.com/article/pharmaceutical-advertising-laws-and-regulations-2026-e066331b823b28e1Pharma Surgeen2026-07-31T11:12:38.000ZPharmaceutical Advertising Laws and Regulations 2026https://www.pharmaradar360.com/article/mumbai-s-girgaon-chowpatty-vendors-wear-fssai-aprons-as-fda-tightens-food-safety-049a183986bc643ePharma Surgeen2026-07-31T11:11:14.000ZMumbai's Girgaon Chowpatty Vendors Wear FSSAI Aprons As FDA Tightens Food Safety Drivehttps://www.pharmaradar360.com/article/ono-pharmaceutical-co-ophlf-q1-earnings-and-revenues-top-estimates-c0ce16c42c75c2b1Pharma Surgeen2026-07-31T11:10:02.000ZOno Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimateshttps://www.pharmaradar360.com/article/sun-pharmaceutical-s-consolidated-net-profit-grows-in-fiscal-q1-d5ce9bb255538ce6Pharma Surgeen2026-07-31T11:09:52.000ZSun Pharmaceutical's Consolidated Net Profit Grows in Fiscal Q1https://www.pharmaradar360.com/article/who-proposes-regulatory-recommendations-to-support-pharmaceutical-decarbonisatio-5ad4c0fee9eaa1b7Pharma Surgeen2026-07-31T11:09:42.000ZWHO proposes regulatory recommendations to support pharmaceutical decarbonisationhttps://www.pharmaradar360.com/article/ai-cognitive-health-startup-mantis-biotech-rethinks-how-women-are-diagnosed-f76c27fb21c72b0cPharma Surgeen2026-07-31T11:00:21.000ZAI Cognitive Health Startup Mantis Biotech Rethinks How Women Are Diagnosedhttps://www.pharmaradar360.com/article/tiziana-reports-reduction-in-brain-inflammation-in-third-multiple-system-atrophy-3334e696b004f349Pharma Surgeen2026-07-31T11:00:00.000ZTiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumabhttps://www.pharmaradar360.com/article/radiopharm-theranostics-reports-business-update-813c0ad8942e4504Pharma Surgeen2026-07-31T11:00:00.000ZRadiopharm Theranostics Reports Business Updatehttps://www.pharmaradar360.com/article/tenax-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-248228c8508f232dPharma Surgeen2026-07-31T11:00:00.000ZTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-55ceb61127210686Pharma Surgeen2026-07-31T10:58:07.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-cort-30-neog-22-bax-7-with-quarterly-results-tra-f6b2f9374c8d5078Pharma Surgeen2026-07-31T10:57:00.000ZBiotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCRhttps://www.pharmaradar360.com/article/tempufen-antalia-pharma-603c48a9f89affafPharma Surgeen2026-07-31T10:53:30.000ZΑπαγόρευση κυκλοφορίας του προϊόντος TEMPUFEN της εταιρείας ANTALIA PHARMA ΜΟΝΟΠΡΟΣΩΠΗ Ι.Κ.Ε.https://www.pharmaradar360.com/article/sun-pharmaceutical-industries-limited-reports-earnings-results-for-the-first-qua-475cdc219e0f989aPharma Surgeen2026-07-31T10:35:43.000ZSun Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026https://www.pharmaradar360.com/article/china-leapfrogs-into-global-biotech-9553b32aef69edf5Pharma Surgeen2026-07-31T10:29:42.000ZChina Leapfrogs into Global Biotechhttps://www.pharmaradar360.com/article/eu-regulatory-roundup-abbvie-pfizer-biontech-and-incyte-net-approvals-8e236f855f7a0bc1Pharma Surgeen2026-07-31T10:26:10.000ZEU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvalshttps://www.pharmaradar360.com/article/proposed-coins-act-seeks-to-restrict-u-s-capital-investment-in-chinese-biotech-s-33e968278fcc1c36Pharma Surgeen2026-07-31T10:20:15.000ZProposed COINS Act Seeks to Restrict U.S. Capital Investment in Chinese Biotech Sectorhttps://www.pharmaradar360.com/article/italfarmaco-announces-managed-entry-agreement-in-georgia-00dd6f291615a17bPharma Surgeen2026-07-31T10:18:26.000ZItalfarmaco Announces Managed Entry Agreement in Georgiahttps://www.pharmaradar360.com/article/boosting-cgt-access-a-global-consideration-with-wide-spanning-benefits-344e64e1b8ac9618Pharma Surgeen2026-07-31T10:16:09.000ZBoosting CGT access: a global consideration with wide-spanning benefitshttps://www.pharmaradar360.com/article/how-pharmacists-are-storing-medicines-in-soaring-temperatures-c698fbec0d94f95fPharma Surgeen2026-07-31T10:09:02.000ZHow pharmacists are storing medicines in soaring temperatureshttps://www.pharmaradar360.com/article/rbf-capital-llc-sells-30-000-shares-of-teva-pharmaceutical-industries-ltd-teva-d1b7f1b4fa010142Pharma Surgeen2026-07-31T10:06:52.000ZRBF Capital LLC Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/a-new-kind-of-hiv-pill-just-passed-its-first-test-in-humans-09e2921a97f76f27Pharma Surgeen2026-07-31T10:03:40.000ZA New Kind of HIV Pill Just Passed Its First Test in Humanshttps://www.pharmaradar360.com/article/sun-pharma-s-quarterly-profit-jumps-on-strength-in-specialty-medicines-a6c59eda54ada6a6Pharma Surgeen2026-07-31T10:03:17.000ZSun Pharma's quarterly profit jumps on strength in specialty medicineshttps://www.pharmaradar360.com/article/pune-food-safety-crackdown-fda-suspends-21-establishments-seizes-50-65-lakh-wort-49b2eafbf6b6b526Pharma Surgeen2026-07-31T09:49:18.000ZPune Food Safety Crackdown: FDA Suspends 21 Establishments, Seizes ₹50.65 Lakh Worth of Goodshttps://www.pharmaradar360.com/article/the-national-gonorrhoea-vaccination-programme-using-4cmenb-vaccine-frequently-as-479b1a7456a61302Pharma Surgeen2026-07-31T09:44:52.000ZThe national gonorrhoea vaccination programme using 4CMenB vaccine: frequently asked questionshttps://www.pharmaradar360.com/article/cordis-project-livemap-live-cell-mapping-of-drug-protein-interactions-across-the-c69f77badafedf2aPharma Surgeen2026-07-31T09:42:43.000ZCORDIS project: LIVEMAP: Live-cell mapping of drug–protein interactions across the human proteomehttps://www.pharmaradar360.com/article/cordis-project-short-tandem-repeat-instability-quantifier-for-next-generation-se-e8e1babd8e9b60d4Pharma Surgeen2026-07-31T09:42:38.000ZCORDIS project: Short Tandem Repeat Instability QuantIfier for Next-Generation sequencinghttps://www.pharmaradar360.com/article/cordis-project-harnessing-biobanking-organ-models-and-patient-empowerment-for-a-b5f2b1795336368aPharma Surgeen2026-07-31T09:40:23.000ZCORDIS project: Harnessing biobanking, Organ models, and Patient Empowerment for a better quality of life for women living within Polyendocrine Metabolic Ovary Syndromehttps://www.pharmaradar360.com/article/cordis-project-targeting-tumour-cell-plasticity-in-colorectal-cancer-78e51cb07241d842Pharma Surgeen2026-07-31T09:40:18.000ZCORDIS project: Targeting Tumour Cell Plasticity in Colorectal Cancerhttps://www.pharmaradar360.com/article/european-drug-manufacturers-under-threat-from-proposed-us-supply-chain-bill-83c2d26863857af7Pharma Surgeen2026-07-31T09:36:09.000ZEuropean drug manufacturers under threat from proposed US supply chain billhttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-mhra-phase-i-accreditation-scheme-0a6f6f31a937b2b5Pharma Surgeen2026-07-31T09:31:24.000ZClinical trials for medicines: MHRA phase I accreditation schemehttps://www.pharmaradar360.com/article/cell-and-gene-therapy-manufacturers-turn-to-specialist-automation-partners-19344ef2e745035aPharma Surgeen2026-07-31T09:21:09.000ZCell and gene therapy manufacturers turn to specialist automation partnershttps://www.pharmaradar360.com/article/measures-from-the-adult-social-care-outcomes-framework-england-2025-to-2026-8bead6d4b132e9c4Pharma Surgeen2026-07-31T09:04:06.000ZMeasures from the adult social care outcomes framework, England: 2025 to 2026https://www.pharmaradar360.com/article/safeguarding-adults-england-2025-to-2026-report-5a1fde56716d266cPharma Surgeen2026-07-31T09:00:50.000ZSafeguarding adults, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/deferred-payment-agreements-england-2025-to-2026-report-2caf38b8e49cf146Pharma Surgeen2026-07-31T08:58:04.000ZDeferred payment agreements, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/adult-social-care-survey-england-2025-to-2026-report-9053469da7332a96Pharma Surgeen2026-07-31T08:49:13.000ZAdult social care survey, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/healthy-child-programme-8d6d3d976dfbbf4fPharma Surgeen2026-07-31T08:30:07.000ZHealthy child programmehttps://www.pharmaradar360.com/article/care-continuity-between-midwifery-and-health-visiting-services-7052bd945725089cPharma Surgeen2026-07-31T08:30:04.000ZCare continuity between midwifery and health visiting serviceshttps://www.pharmaradar360.com/article/fda-regulatory-hurdles-expose-rare-disease-drug-crisis-b970ef9d24148159Pharma Surgeen2026-07-31T08:30:00.000ZFDA Regulatory Hurdles Expose Rare Disease Drug Crisishttps://www.pharmaradar360.com/article/unlocking-the-east-of-england-s-life-sciences-potential-reflections-from-our-reg-5210f7af0795e268Pharma Surgeen2026-07-31T08:29:55.000ZUnlocking the East of England’s life sciences potential: Reflections from our regional roundtablehttps://www.pharmaradar360.com/article/kosdaq-shift-to-ai-and-chips-hits-ingenia-therapeutics-ipo-demand-chosunbiz-780eca151a03e9ddPharma Surgeen2026-07-31T08:28:00.000ZKOSDAQ shift to AI and chips hits Ingenia Therapeutics IPO demand - CHOSUNBIZhttps://www.pharmaradar360.com/article/dhsc-spending-over-500-9d0eec9bf491adbdPharma Surgeen2026-07-31T08:23:03.000ZDHSC spending over £500https://www.pharmaradar360.com/article/dhsc-spending-over-500-june-2026-6a9f886019dc866cPharma Surgeen2026-07-31T08:22:59.000ZDHSC: spending over £500, June 2026https://www.pharmaradar360.com/article/dimensional-fund-advisors-lp-purchases-73-410-shares-of-teva-pharmaceutical-indu-51ad3d1262ce51caPharma Surgeen2026-07-31T08:13:52.000ZDimensional Fund Advisors LP Purchases 73,410 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ono-pharmaceutical-profit-rose-despite-revenue-decline-driven-by-cost-cuts-and-o-f66830dc014a1c31Pharma Surgeen2026-07-31T08:09:44.000ZOno Pharmaceutical : Profit rose despite revenue decline, driven by cost cuts and overseas sales growthhttps://www.pharmaradar360.com/article/apnimed-s-ipo-dream-comes-true-with-upsized-192m-ipo-to-fund-sleep-apnea-pill-la-ffdc56d726c02f5dPharma Surgeen2026-07-31T08:09:06.000ZApnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchhttps://www.pharmaradar360.com/article/b-riley-initiates-4d-molecular-therapeutics-stock-coverage-with-buy-rating-04e9dadbbb279687Pharma Surgeen2026-07-31T08:08:00.000ZB.Riley initiates 4D Molecular Therapeutics stock coverage with buy ratinghttps://www.pharmaradar360.com/article/the-ai-ready-factory-how-itot-integration-transforms-pharmaceutical-manufacturin-82aad78a3caff2ccPharma Surgeen2026-07-31T08:03:45.000ZThe AI-Ready Factory How ITOT Integration Transforms Pharmaceutical Manufacturing Data Into Actionable Intelligencehttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-shares-rise-2-03-in-today-s-session-5a04c8b677c45d35Pharma Surgeen2026-07-31T08:01:08.000ZSun Pharmaceutical Industries Shares Rise 2.03% in Today's Sessionhttps://www.pharmaradar360.com/article/mapping-ai-drug-discovery-the-companies-behind-biotech-s-most-searched-technolog-68c00e034de4829bPharma Surgeen2026-07-31T07:59:38.000ZMapping AI Drug Discovery: The Companies Behind Biotech’s Most-Searched Technologyhttps://www.pharmaradar360.com/article/eyepoint-completes-enrollment-of-duravyu-phase-3-trials-for-diabetic-macular-ede-018317361d37222bPharma Surgeen2026-07-31T07:37:59.000ZEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edemahttps://www.pharmaradar360.com/article/abivax-clears-pre-nda-meeting-with-fda-for-obefazimod-in-ulcerative-colitis-48c0d35604074be2Pharma Surgeen2026-07-31T07:37:59.000ZAbivax Clears Pre-NDA Meeting with FDA for Obefazimod in Ulcerative Colitishttps://www.pharmaradar360.com/article/selinexor-phase-3-trial-misses-primary-endpoint-in-endometrial-cancer-a285d71605c0e50fPharma Surgeen2026-07-31T07:37:59.000ZSelinexor Phase 3 Trial Misses Primary Endpoint in Endometrial Cancerhttps://www.pharmaradar360.com/article/latigo-s-ltg-001-phase-2b-data-signals-a-new-design-standard-for-nav1-8-pain-tri-6fc95c4eef6150a8Pharma Surgeen2026-07-31T07:37:59.000ZLatigo’s LTG-001 Phase 2b Data Signals a New Design Standard for NaV1.8 Pain Trialshttps://www.pharmaradar360.com/article/mid-day-exclusive-citizens-must-demand-standardised-food-inside-tukaram-mundhe-s-c6cdd620161a56bdPharma Surgeen2026-07-31T07:32:00.000ZMid-Day Exclusive | 'Citizens must demand standardised food': Inside Tukaram Mundhe's food safety crackdown